Retatrutide Review: What Research Shows About This Triple Agonist
Retatrutide is the newest name in the incretin space, going one receptor further than the dual agonists. Here’s what the mechanism and early data suggest. Research reference only.
The Short Answer
Retatrutide is a triple agonist that activates GIP, GLP-1, and glucagon receptors simultaneously, and early trial data points to some of the strongest weight-loss effects reported in the class. It’s the leading edge of incretin research, but it’s still in clinical development.
Mechanism: Three Targets, Not Two
Retatrutide’s defining feature is the glucagon receptor — that third target is thought to raise energy expenditure on top of the appetite and glycemic effects from GIP and GLP-1. That extra receptor is what sets it apart from dual agonists like Tirzepatide.
- Class: triple receptor agonist (GIP + GLP-1 + glucagon)
- Extra target: glucagon receptor (energy expenditure)
- Status: in clinical development, not yet approved
Research Status
Retatrutide is still in late-stage clinical trials, so the published human data is smaller than for Tirzepatide or Semaglutide — but the early efficacy signals are strong enough that it’s a heavily watched candidate. “Not yet approved” is the key caveat for any sourcing decision.
Sourcing and Purity
Research-grade Retatrutide should be ≥98% pure by HPLC with mass spectrometry confirmation and a batch-matched COA, and because it’s a new, in-demand target, mislabeled or under-dosed material is a real risk. Verify the source carefully given how new the compound is.
FAQ
Q: What is Retatrutide?
A: Retatrutide is a triple agonist that activates GIP, GLP-1, and glucagon receptors, studied for weight loss and metabolic effects. It’s in clinical development, not yet approved.
Q: How is Retatrutide different from Tirzepatide?
A: Retatrutide adds a glucagon-receptor target to Tirzepatide’s dual GIP/GLP-1 mechanism, which is thought to raise energy expenditure. The third receptor is the key difference.
Q: Is Retatrutide approved?
A: No — Retatrutide is still in clinical trials and has no regulatory approval. It’s available only as a research reference compound.